Figure 6.

Polyacrylamide gel staining for phosphoproteins and total protein. Panel A, nondenaturing polyacrylamide gel stained for phosphoproteins with Pro-Q Diamond: Lanes A1 and A2; 10 and 5 µl of human plasma treated with CBDP to inhibit 100% of the butyrylcholinesterase activity. Lanes A3 and A4; 10 µl of unlabeled, control human plasma. Ten microliters of human plasma contains 0.04 micrograms of butyrylcholinesterase. Lanes A5 and A6; 5 µl of control human plasma. Lane A7, 2.1 µg of 50% purified control human butyrylcholinesterase (with a specific activity of 360 units/mg). Lane A8, 0.4 µg of 50% purified control human butyrylcholinesterase. Panel B, SDS polyacrylamide gel stained for phosphoproteins with Pro-Q Diamond; and Panel C, SDS polyacrylamide gel counterstained for protein with Coomassie Blue R-250: Lanes B1 and C1; 0.8 µl control human plasma. Lanes B2 and C2; 0.8 µl of CBDP-treated human plasma (100% inhibition of butyrylcholinesterase). Lanes B3 and C3; 5 µg of 8% purified butyrylcholinesterase (with specific activity of 60 units/mg). Lanes B4 and C4; 5 µg of pure human albumin. Lanes B5 and C5; 5 µg of 50% purified untreated control human butyrylcholinesterase. Lanes B6 and C6; 0.9 µg of 50% pure butyrylcholinesterase treated with CBDP to inhibit 100% of the activity (CBDP-butyrylcholinesterase). Lanes B7 and C7; 2.2 µg of CBDP-butyrylcholinesterase. Lanes B8 and C8; 3.5 µg of CBDP-butyrylcholinesterase. The 85 kDa band is butyrylcholinesterase. The 65 kDa band is albumin.